This article is more than 5 years old. Information may no longer be current.

VIDEO: Ixekizumab shows continued efficacy for 60-week treatment of psoriasis

WASHINGTON — In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his research showing that ixekizumab (Eli Lilly and Company) had continued efficacy in treating patients with psoriasis through week 60.

Blauvelt, president and investigator of Oregon Medical Research Center, Portland, presented results from the UNCOVER-3 study at a late-breaking research forum.